Last edition
News about "IGI Therapeutics SA"
Ichnos Glenmark Innovation Secures USD 700M Upfront in AbbVie Licensing Deal for ISB 2001
Ichnos Glenmark Innovation (IGI) has received an upfront payment of USD 700 million from AbbVie under the terms of their recently announced global licensing agreement for IGI’s lead investigational asset, ISB 2001.
IGI Therapeutics SA | 09/09/2025 | By Dineshwori | 133
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members